GLP-1 / glucagon dual agonist (investigational)
An investigational dual GLP-1/glucagon receptor agonist studied for weight management and liver disease.
Early-phase trial results have drawn interest; long-term data is still being collected.
Unregulated outside trials; effects are monitored within the trial setting.
Investigational — not approved or marketed as a medicine in Australia.
No lawful consumer supply. Access is only via an approved clinical trial.
This entry is general information about Survodutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.